SNY Quote, Financials, Valuation and Earnings

AstraZeneca PLC has a net margin of 36.7% compared to Sanofi's net margin of 16.69%. Sanofi's return on equity of 12.45% beat AstraZeneca PLC's return on equity of 22.01%.

Sanofi has a consensus price target of $60.13, signalling upside risk potential of 22.96%. On the other hand AstraZeneca PLC has an analysts' consensus of $96.86 which suggests that it could grow by 7.59%. Given that Sanofi has higher upside potential than AstraZeneca PLC, analysts believe Sanofi is more attractive than AstraZeneca PLC.

Sanofi has a beta of 0.446, which suggesting that the stock is 55.394% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.315, suggesting its less volatile than the S&P 500 by 68.471%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.49%. AstraZeneca PLC offers a yield of 1.74% to investors and pays a quarterly dividend of $0.52 per share. Sanofi pays 66.53% of its earnings as a dividend. AstraZeneca PLC pays out 66.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are smaller than AstraZeneca PLC quarterly revenues of $15.1B. Sanofi's net income of $4.5B is higher than AstraZeneca PLC's net income of $2.5B. Notably, Sanofi's price-to-earnings ratio is 12.21x while AstraZeneca PLC's PE ratio is 29.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.81x versus 4.84x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 36.7% compared to Sanofi's net margin of -19.69%. Sanofi's return on equity of 12.45% beat Moderna, Inc.'s return on equity of -30.18%.

Sanofi has a consensus price target of $60.13, signalling upside risk potential of 22.96%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Moderna, Inc. has higher upside potential than Sanofi, analysts believe Moderna, Inc. is more attractive than Sanofi.

Sanofi has a beta of 0.446, which suggesting that the stock is 55.394% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.49%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Moderna, Inc. quarterly revenues of $1B. Sanofi's net income of $4.5B is higher than Moderna, Inc.'s net income of -$200M. Notably, Sanofi's price-to-earnings ratio is 12.21x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.81x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of 36.7% compared to Sanofi's net margin of -287.29%. Sanofi's return on equity of 12.45% beat Novavax, Inc.'s return on equity of --.

Sanofi has a consensus price target of $60.13, signalling upside risk potential of 22.96%. On the other hand Novavax, Inc. has an analysts' consensus of $12.67 which suggests that it could grow by 84.65%. Given that Novavax, Inc. has higher upside potential than Sanofi, analysts believe Novavax, Inc. is more attractive than Sanofi.

Sanofi has a beta of 0.446, which suggesting that the stock is 55.394% less volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.478%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.49%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Novavax, Inc. quarterly revenues of $70.4M. Sanofi's net income of $4.5B is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Sanofi's price-to-earnings ratio is 12.21x while Novavax, Inc.'s PE ratio is 3.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.81x versus 1.09x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 36.7% compared to Sanofi's net margin of 38.89%. Sanofi's return on equity of 12.45% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Sanofi has a consensus price target of $60.13, signalling upside risk potential of 22.96%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.07%. Given that Sanofi has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Sanofi is more attractive than Regeneron Pharmaceuticals, Inc..

Sanofi has a beta of 0.446, which suggesting that the stock is 55.394% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.49%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Sanofi pays 66.53% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Sanofi's net income of $4.5B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Sanofi's price-to-earnings ratio is 12.21x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.81x versus 5.59x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.